{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:52:59Z","timestamp":1770292379773,"version":"3.49.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although gout is a common, well-recognized, and extensively researched rheumatologic disease, it continues to be underappreciated and undertreated. Although the prevalence of gout has been rising over the past several decades, adherence to urate lowering therapy continues to be suboptimal. Recent studies have underscored the potential success of guideline-directed therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Adherence to gout treatment continues to be suboptimal according to multinational metaanalyses. Moreover, studies measuring adherence are prone to overestimation and each methodologic approach has intrinsic limitations. Adherence may be analyzed from the perspective of patient adherence to taking a medication, or provider adherence to treatment guidelines. In addition to considering traditional risk factors, adherence should be viewed through the lens of healthcare disparities. The RAmP-Up trial and Nottingham Gout Treatment trial demonstrate the success of protocolized gout treatment using existing guidelines for reference.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Standardized gout treatment protocols should be established for all primary care and specialty practices. Two successful methods of improving adherence include using nonphysician providers to coordinate urate lowering therapy titration and monitoring serum urate. Having more frequent outpatient visits to focus on direct patient care and education has also been successful.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000774","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T05:39:22Z","timestamp":1608183562000},"page":"128-134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Adherence to gout guidelines: where do we stand?"],"prefix":"10.1097","volume":"33","author":[{"given":"Gary H.","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine"},{"name":"Department of Medicine, Rheumatology Section, New York Harbor Healthcare System, New York Campus, United States Department of Veterans Affairs, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine"},{"name":"Department of Medicine, Rheumatology Section, New York Harbor Healthcare System, New York Campus, United States Department of Veterans Affairs, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Toprover","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine"},{"name":"Department of Medicine, Rheumatology Section, New York Harbor Healthcare System, New York Campus, United States Department of Veterans Affairs, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,15]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","article-title":"Gout and hyperuricaemia in the USA: prevalence and trends","volume":"58","author":"Singh","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","article-title":"Epidemiology of gout","volume":"40","author":"Roddy","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","article-title":"The global burden of gout: estimates from the Global Burden of Disease 2010 study","volume":"73","author":"Smith","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2013.04.003","article-title":"A revised estimate of the burden of illness of gout","volume":"75","author":"Wertheimer","year":"2013","journal-title":"Curr Ther Res Clin Exp"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.21837","article-title":"Gout-related healthcare utilization in US emergency departments, 2006 through 2008","volume":"65","author":"Garg","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40273-015-0288-5","article-title":"A systematic review of the economic and humanistic burden of gout","volume":"33","author":"Shields","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","article-title":"Medication adherence in gout: a systematic review","volume":"66","author":"De Vera","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"e017542","DOI":"10.1136\/bmjopen-2017-017542","article-title":"Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis","volume":"8","author":"Yin","year":"2018","journal-title":"BMJ Open"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","article-title":"Rates of adherence and persistence with allopurinol therapy among gout patients in Israel","volume":"52","author":"Zandman-Goddard","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"R12-20250526","first-page":"1575","article-title":"Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims","volume":"31","author":"Riedel","year":"2004","journal-title":"J Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/ijcp.12604","article-title":"Allopurinol adherence among patients with gout: an Italian general practice database study","volume":"69","author":"Mantarro","year":"2015","journal-title":"Int J Clin Pract"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","article-title":"Adherence and persistence to urate-lowering therapies in the Irish setting","volume":"35","author":"McGowan","year":"2016","journal-title":"Clin Rheumatol"},{"key":"R15-20250526","first-page":"44","article-title":"Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout","volume":"30","author":"de Klerk","year":"2003","journal-title":"J Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3109\/14397595.2016.1170914","article-title":"Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting","volume":"26","author":"Lee","year":"2016","journal-title":"Mod Rheumatol"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.140588","article-title":"Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system","volume":"42","author":"Rashid","year":"2015","journal-title":"J Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently: a qualitative study","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illn"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/00325481.2016.1113840","article-title":"A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift","volume":"128","author":"Khanna","year":"2016","journal-title":"Postgrad Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clinthera.2016.12.011","article-title":"Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review","volume":"39","author":"Keenan","year":"2017","journal-title":"Clin Ther"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/1756-185X.13566","article-title":"Improving adherence to urate-lowering therapy in people living with gout","volume":"22","author":"Coleshill","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/BOR.0000000000000583","article-title":"Patient perspectives in gout: a review","volume":"31","author":"Singh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/acr2.11121","article-title":"Management of gout in the United States: a claims-based analysis","volume":"2","author":"Edwards","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3810\/pgm.2014.05.2774","article-title":"Physician adherence to ACR gout treatment guidelines: perception versus practice","volume":"126","author":"Oderda","year":"2014","journal-title":"Postgrad Med"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/ard.2008.092619","article-title":"Opportunities for improving medication use and monitoring in gout","volume":"68","author":"Singh","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00296-013-2935-5","article-title":"Allopurinol use in a New Zealand population: prevalence and adherence","volume":"34","author":"Horsburgh","year":"2014","journal-title":"Rheumatol Int"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"631","DOI":"10.31128\/AJGP-04-19-4909","article-title":"The challenges of managing gout in primary care: results of a best-practice audit","volume":"48","author":"Stamp","year":"2019","journal-title":"Aust J Gen Pract"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","article-title":"Uric acid lowering therapy: prescribing patterns in a large cohort of older adults","volume":"67","author":"Solomon","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1186\/ar4524","article-title":"Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study","volume":"16","author":"Singh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout 2020","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00296-019-04333-5","article-title":"Pharmacist-managed titration of urate-lowering therapy to streamline gout management","volume":"39","author":"Huang","year":"2019","journal-title":"Rheumatol Int"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"R37-20250526","first-page":"1","article-title":"Japanese Society of Gout and Uric & Nucleic Acids 2019 guidelines for management of hyperuricemia and gout, 3rd edition","volume":"44","author":"Hisatome","year":"2020","journal-title":"Gout Uric Nucleic Acids"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jbspin.2020.05.002","article-title":"2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy","volume":"87","author":"Pascart","year":"2020","journal-title":"Joint Bone Spine"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/art.40929","article-title":"Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial","volume":"71","author":"Dalbeth","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.41063","article-title":"Effects of conventional uric acid-lowering therapy on monosodium urate crystal deposits","volume":"72","author":"Ellmann","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"e15021","DOI":"10.2196\/15021","article-title":"Association between user engagement of a mobile health app for gout and improvements in self-care behaviors: randomized controlled trial","volume":"7","author":"Serlachius","year":"2019","journal-title":"JMIR Mhealth Uhealth"},{"key":"R43-20250526","first-page":"575","article-title":"Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: results of Nottingham Gout Treatment Trial follow-up study","volume":"59","author":"Fuller","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:22:02Z","timestamp":1748294522000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,15]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000774","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,15]]}}}